Key result
Non-pegylated liposomal doxorubicin offers an optimized toxicity profile, allowing safe administration beyond the standard maximum cumulative dose in HER2-negative metastatic breast cancer.
Why the study?
Anthracyclines are limited by cardiotoxicity, and the increasing complexity of HER2-negative metastatic breast cancer treatments prompted a review of non-pegylated liposomal doxorubicin.
Does non-pegylated liposomal doxorubicin provide a safe and effective treatment option with reduced cardiotoxicity in HER2-negative metastatic breast cancer?
Does non-pegylated liposomal doxorubicin provide a safe and effective treatment option with reduced cardiotoxicity in HER2-negative metastatic breast cancer?
Non-pegylated liposomal doxorubicin offers a safer anthracycline option with reduced cardiotoxicity for patients with HER2-negative metastatic breast cancer.
Answers are grounded in this paper and cite their sources.
May support extended dosing in HER2-negative metastatic breast cancer; leaves open randomized confirmation of cardiotoxicity reduction.
Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non-pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450–480 mg/m2. Following three pivotal first-line phase III trials in HER2-negative metastatic BC (MBC), this drug was finally approved in combination with cyclophosphamide in this specific setting. Given the increasing complexity of the therapeutic scenario of HER2-negative MBC, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms.
No takes yet. Share an insight, caveat, or question.
Schettini et al. (2021) conducted a review in HER2-negative metastatic breast cancer. Non-pegylated liposomal doxorubicin (NPLD) was evaluated. Non-pegylated liposomal doxorubicin offers an optimized toxicity profile, allowing safe administration beyond the standard maximum cumulative dose in HER2-negative metastatic breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: